June is ALS Awareness Month  Support an ALS EventEvents CalendarHealthcare ProvidersClinical TrialsALS and Youth

Phase II Clinical Results for NP001 Therapy from Neuraltus Pharmaceuticals

Results from the Phase II study of NP001, a drug targeting inflammation caused by immune cells called microglia, demonstrated a non-statistically significant slowing of disease progression by 13-19%.

However, extended analysis revealed that a subset of individuals taking NP001 experienced a complete arrest in disease progression compared to placebo controls over a six month period. NP001 was also found to be safe without any significant adverse events. These results have led Neuraltus to plan a Phase III trial for the second half of 2013.

For more information please visit: